Treatment of progressive multiple sclerosis: what works, what does not, and what is needed

Lancet Neurology
Anthony FeinsteinAlbert C Lo

Abstract

Disease-modifying drugs have mostly failed as treatments for progressive multiple sclerosis. Management of the disease therefore solely aims to minimise symptoms and, if possible, improve function. The degree to which this approach is based on empirical data derived from studies of progressive disease or whether treatment decisions are based on what is known about relapsing-remitting disease remains unclear. Symptoms rated as important by patients with multiple sclerosis include balance and mobility impairments, weakness, reduced cardiovascular fitness, ataxia, fatigue, bladder dysfunction, spasticity, pain, cognitive deficits, depression, and pseudobulbar affect; a comprehensive literature search shows a notable paucity of studies devoted solely to these symptoms in progressive multiple sclerosis, which translates to few proven therapeutic options in the clinic. A new strategy that can be used in future rehabilitation trials is therefore needed, with the adoption of approaches that look beyond single interventions to concurrent, potentially synergistic, treatments that maximise what remains of neural plasticity in patients with progressive multiple sclerosis.

References

Apr 30, 1998·The British Journal of Medical Psychology·L VleugelsH van der Ploeg
Jun 17, 2000·Archives of Physical Medicine and Rehabilitation·R GosselinkM Decramer
Jan 25, 2002·Multiple Sclerosis : Clinical and Laboratory Research·S G LynchD R Denney
Apr 12, 2002·Neurorehabilitation and Neural Repair·K ArmutluG Nurlu
Aug 27, 2002·Journal of Neurology·Francesco PattiArturo Reggio
Jun 6, 2003·The American Journal of Occupational Therapy : Official Publication of the American Occupational Therapy Association·Susan M VanageVirgil Mathiowetz
Oct 1, 2004·Brain : a Journal of Neurology·Katrin MorgenLeonardo G Cohen
Jun 18, 2005·Archives of Clinical Neuropsychology : the Official Journal of the National Academy of Neuropsychologists·Douglas R DenneySharon G Lynch
Sep 20, 2005·Lancet Neurology·Jürg Kesselring, Serafin Beer
Jan 3, 2006·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·M W NortvedtJ G Maeland
Jul 1, 2006·Neurological Research·Ferhan SoyuerUnal Erkorkmaz
Sep 5, 2006·Pain·Olympia HadjimichaelTimothy Vollmer
Nov 8, 2006·Multiple Sclerosis : Clinical and Laboratory Research·C L MartinM P Galea
Feb 14, 2007·Multiple Sclerosis : Clinical and Laboratory Research·M W NortvedtK M Myhr
Apr 25, 2007·Multiple Sclerosis : Clinical and Laboratory Research·Barbara GiesserSusan Harkema
Apr 28, 2007·Multiple Sclerosis : Clinical and Laboratory Research·L MillerL Wood
Sep 21, 2007·Multiple Sclerosis : Clinical and Laboratory Research·E W PetersonM L Finlayson
Sep 25, 2007·Annals of Neurology·Vinay KalsiClare J Fowler
Feb 8, 2008·Psychosomatic Medicine·Kirsten van KesselElizabeth Robinson
May 16, 2008·Journal of Neurology·R H B BenedictR L Carpenter
May 29, 2008·Multiple Sclerosis : Clinical and Laboratory Research·C HeesenS M Gold
Jun 7, 2008·Multiple Sclerosis : Clinical and Laboratory Research·M KochJ De Keyser
Jun 25, 2008·Multiple Sclerosis : Clinical and Laboratory Research·G KochD Centonze
Aug 30, 2008·Multiple Sclerosis : Clinical and Laboratory Research·M GironiG Martino
Oct 11, 2008·Multiple Sclerosis : Clinical and Laboratory Research·D Cattaneo, J Jonsdottir
Apr 3, 2010·Clinical Rehabilitation·V L Stevenson
Jul 16, 2010·Current Neurology and Neuroscience Reports·Deborah M Miller, Rebecca Allen
Jul 31, 2010·Journal of Neuroengineering and Rehabilitation·Elena VergaroVittorio Sanguineti
Sep 14, 2010·Multiple Sclerosis : Clinical and Laboratory Research·Valentina TomassiniPaul M Matthews
Feb 3, 2011·Journal of Neurology·Francesco MoriDiego Centonze

❮ Previous
Next ❯

Citations

Jan 6, 2016·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Afsaneh ShiraniOlaf Stüve
Mar 12, 2016·Progress in Lipid Research·Fabio Arturo IannottiStefania Petrosino
Oct 7, 2015·Journal of the Neurological Sciences·Mojtaba FarjamAbdolmohamad Rostami
Apr 18, 2015·Acta Physiologica·P B Persson
Aug 8, 2015·Nature Reviews. Immunology·Calliope A DendrouManuel A Friese
Mar 17, 2015·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Heinz WiendlStefan Schwab
Apr 20, 2016·Current Treatment Options in Neurology·Divyanshu DubeyOlaf Stüve
Mar 17, 2015·Lancet Neurology·Alan J Thompson
Mar 17, 2015·Lancet Neurology·Timothy CoetzeeTrevis L Gleason
Jun 18, 2016·Molecular Neurobiology·Xiang LiXing-Shu Chen
Jan 12, 2016·Expert Review of Pharmacoeconomics & Outcomes Research·Adrien Gras, Julie Broughton
Feb 28, 2016·Multiple Sclerosis : Clinical and Laboratory Research·Emanuele D'AmicoFrancesco Patti
Dec 15, 2015·Multiple Sclerosis : Clinical and Laboratory Research·Sofia StraudiNino Basaglia
Jan 10, 2016·Neurorehabilitation and Neural Repair·Ilse LamersPeter Feys
Jul 26, 2017·Multiple Sclerosis : Clinical and Laboratory Research·Francisco Alejandro Rodriguez-LealTjalf Ziemssen
Jul 29, 2017·Nature Reviews. Neurology·Anthony Feinstein
Dec 8, 2017·Journal of Cellular Physiology·Patrick O AzevedoAlexander Birbrair
Jul 29, 2016·Multiple Sclerosis : Clinical and Laboratory Research·Peter FeysStine Lykke Andersen
May 18, 2018·Expert Review of Neurotherapeutics·Jessica F BairdRobert W Motl
Nov 21, 2017·Multiple Sclerosis : Clinical and Laboratory Research·Jennifer Freeman
Jul 11, 2018·The Journal of Immunology : Official Journal of the American Association of Immunologists·Xin WanChuanlai Shen
Oct 24, 2018·Multiple Sclerosis : Clinical and Laboratory Research·Per Soelberg SorensenGiancarlo Comi
May 11, 2019·Multiple Sclerosis : Clinical and Laboratory Research·Jean-Pierre R FaletFraser Moore
May 23, 2019·Neurodegenerative Disease Management·Leslie Beth HerbertAmrita Bhowmick
Jun 5, 2016·Continuum : Lifelong Learning in Neurology·Mary Alissa Willis, Robert J Fox
Jun 5, 2016·Continuum : Lifelong Learning in Neurology·Patricia K Coyle
Aug 31, 2019·Multiple Sclerosis : Clinical and Laboratory Research·Peter Feys, Sofia Straudi
Apr 19, 2020·Current Opinion in Neurology·Diego CentonzePeter Feys
Nov 2, 2018·Scientific Reports·Daniel Z RadeckiAlexander Gow
Apr 10, 2020·Journal of Neural Engineering·Andreas SchwarzGernot R Müller-Putz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Ataxias (MDS)

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Ataxia

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Ataxias

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on different types of ataxias here.

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.

Botulism

Botulism is a rare but serious paralytic illness caused by a nerve toxin that is produced by the bacterium clostridium botulinum. Discover the latest research on botulism here.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Botulism (ASM)

Botulism is a rare but serious paralytic illness caused by a nerve toxin that is produced by the bacterium clostridium botulinum. Discover the latest research on botulism here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.